Literature DB >> 10807686

Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.

T T Kung1, Y Crawley, B Luo, S Young, W Kreutner, R W Chapman.   

Abstract

This study investigates the role of adrenal-derived catecholamines and corticosterone on the inhibition by rolipram, a phosphodiesterase (PDE)-4 inhibitor, of pulmonary eosinophilia and airway hyperresponsiveness (AHR) in allergic mice. The following experimental groups were studied in mice sensitized and challenged with ovalbumin (OVA): normal, adrenalectomized, propranolol (beta-adrenoceptor antagonist) and metyrapone (corticosterone synthesis inhibitor) treated. These interventions were studied both in the absence and in the presence of rolipram. Eosinophil numbers in the bronchoalveolar lavage (BAL) and AHR to methacholine were measured 24 h after OVA challenge. Treatment of sensitized mice with rolipram (0.3 - 10 mg kg(-1), p.o.), inhibited pulmonary eosinophilia and the AHR to methacholine in OVA-challenged mice. Adrenalectomy increased the number of eosinophils in the BAL of OVA-challenged mice but had no effect on AHR to methacholine. Adrenalectomy attenuated both the rolipram-induced inhibition of BAL eosinophilia and AHR to methacholine in OVA challenged mice. Propranolol (10 mg kg(-1), p.o.) had no effect on the inhibition of eosinophilia by rolipram but attenuated the inhibition of AHR to methacholine in OVA challenged mice. On the other hand, metyrapone (10 mg kg(-1), p.o.) attenuated the inhibition of eosinophilia by rolipram but had no effect on the inhibition of AHR to methacholine in OVA challenged mice. Metyrapone-treatment alone increased the number of eosinophils in the BAL of OVA-challenged mice. These results identify an important role for adrenal-derived catecholamines and corticosterone on the inhibition of pulmonary eosinophilia and AHR by rolipram in allergic mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807686      PMCID: PMC1572069          DOI: 10.1038/sj.bjp.0703308

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

Review 1.  Asthma and inflammation.

Authors:  A B Kay
Journal:  J Allergy Clin Immunol       Date:  1991-05       Impact factor: 10.793

2.  Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.

Authors:  D C Underwood; S Bochnowicz; R R Osborn; C J Kotzer; M A Luttmann; D W Hay; P D Gorycki; S B Christensen; T J Torphy
Journal:  J Pharmacol Exp Ther       Date:  1998-12       Impact factor: 4.030

3.  Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness.

Authors:  K G Tournoy; J C Kips; C Schou; R A Pauwels
Journal:  Clin Exp Allergy       Date:  2000-01       Impact factor: 5.018

4.  Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response.

Authors:  D E Griswold; E F Webb; J Breton; J R White; P J Marshall; T J Torphy
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

5.  Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.

Authors:  D C Underwood; C J Kotzer; S Bochnowicz; R R Osborn; M A Luttmann; D W Hay; T J Torphy
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

6.  Effects of rolipram on responses to acute and chronic antigen exposure in monkeys.

Authors:  C R Turner; C J Andresen; W B Smith; J W Watson
Journal:  Am J Respir Crit Care Med       Date:  1994-05       Impact factor: 21.405

7.  Characterization of a murine model of allergic pulmonary inflammation.

Authors:  T T Kung; H Jones; G K Adams; S P Umland; W Kreutner; R W Egan; R W Chapman; A S Watnick
Journal:  Int Arch Allergy Immunol       Date:  1994-09       Impact factor: 2.749

8.  Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma.

Authors:  P J Mauser; A Pitman; A Witt; X Fernandez; J Zurcher; T Kung; H Jones; A S Watnick; R W Egan; W Kreutner
Journal:  Am Rev Respir Dis       Date:  1993-12

9.  Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo.

Authors:  D Raeburn; J A Karlsson
Journal:  J Pharmacol Exp Ther       Date:  1993-12       Impact factor: 4.030

10.  Effect of intravenous aminophylline on plasma levels of catecholamines and related cardiovascular and metabolic responses in man.

Authors:  R E Vestal; C E Eiriksson; B Musser; L K Ozaki; J B Halter
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

View more
  11 in total

Review 1.  PDE4 inhibitors: current status.

Authors:  D Spina
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

Review 2.  Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases.

Authors:  Theerasuk Kawamatawong
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

3.  Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.

Authors:  P M Silva; A C Alves; M F Serra; A L Pires; J P Silva; E O Barreto; R S Cordeiro; P J Jose; M M Teixeira; V Lagente; M A Martins
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 4.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.

Authors:  M-J Sanz; J Cortijo; M A Taha; M Cerdá-Nicolás; E Schatton; B Burgbacher; J Klar; H Tenor; C Schudt; A C Issekutz; A Hatzelmann; E J Morcillo
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

6.  Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipram.

Authors:  A C Soares; D G Souza; V Pinho; A T Vieira; M M Barsante; J R Nicoli; M Teixeira
Journal:  Br J Pharmacol       Date:  2003-11       Impact factor: 8.739

7.  Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms.

Authors:  L A Carvalho; B A Garner; T Dew; H Fazakerley; C M Pariante
Journal:  Eur Neuropsychopharmacol       Date:  2010-03-15       Impact factor: 4.600

Review 8.  What have transgenic and knockout animals taught us about respiratory disease?

Authors:  Y R Vasquez; D Spina
Journal:  Respir Res       Date:  2000-08-03

9.  Quercetin acutely relaxes airway smooth muscle and potentiates β-agonist-induced relaxation via dual phosphodiesterase inhibition of PLCβ and PDE4.

Authors:  Elizabeth A Townsend; Charles W Emala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-07-19       Impact factor: 5.464

10.  Can we find better bronchodilators to relieve asthma symptoms?

Authors:  Elizabeth A Townsend; Peter D Yim; George Gallos; Charles W Emala
Journal:  J Allergy (Cairo)       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.